REGISTER now: Visser ai webinar - Beyond the ai hype: ai in patent prosecution
​

INTA 2026 Essentials: Where to stay, what to see and what to do

No items found.
​
June 3, 2025

Download PDF

Table of contents
  • Toc Heading
  • Toc Heading
No items found.

Introduction

We’re thrilled that INTA 2026 is coming to London—the city where our firm was proudly founded and continues to thrive!

The recent INTA conference in San Diego was fabulous. We believe INTA in London will be a very exciting experience, but quite different from San Diego. London is a vibrant, bustling world-class metropolis that seamlessly blends rich history, a dynamic culinary scene and cutting edge innovation. The sheer size of London and the fact that the conference venue Excel is in East London and quite some way away from Central London, will make it even more important to plan your conference well ahead. Staying near any of the stations of the new Elizabeth Line that will take you to Excel, will probably be a good choice for most.

So to help you make the most of your visit, our London-based team has curated a go-to guide covering:

  • Where to stay
  • Things to do and see
  • Where to eat and drink
  • How to get around
  • Apps to download before you arrive

Let's get started!

Places to stay

Excel/London Docklands

Where the INTA conference centre will be located


Canary Wharf

14 minutes on the Elizabeth Line to the Excel


Central London landmark hotels

Things to do and see

Landmarks to see

  • The London Eye
  • Tower of London
  • Buckingham Palace
  • Houses of Parliament and Big Ben
  • The British Museum
  • St Paul's Cathedral
  • Shakespeare's Globe Theatre


Activities

  • Watch a West End Show
  • Climb the O2
  • Visit Madame Tussauds
  • Check out the V&A museum at both its original location in South Kensington and its new site in East London
  • Visit the Bank of England
  • Eat afternoon tea at the Ritz or Fortnum & Mason
  • Visit us in  Holborn


Shopping and markets

  • Oxford Street
  • Covent Garden
  • Camden Market
  • Borough Market

Places to eat

Excel/London Docklands


Canary Wharf


Liverpool Street

‍

Rooftop bars

How to get around

From Custom House where the Excel is located, there are two tube lines:

View the tube map here. Visit the ExCel London website here.

Alternative ways to get around:

  • Cable car  from IFS Cloud Royal Docks to Greenwich Peninsula - 9-minute walk from the Excel London
  • Uber boat  along the Thames


Taxis:


Bikes:

Apps to download

  • Citymapper - The ultimate transport app, to help you navigate around London
  • Visit London - London's official visitor guide
  • Open Table - Discover and book restaurants

‍

The Latest Thought Leadership pieces in the Content Hub

See all articles

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

​
对 EIP 的职业感兴趣吗？

查看空缺职位

Heading
This is some text inside of a div block.
This is some text inside of a div block.
​

Latest Insights

Showing 0 of 100
Filters
The UPC After Three Years: From Experiment to Enforcement Forum
15 July 2026
1,282 cases filed at the UPC in three years: infringement actions have surged while revocation filings stayed flat, easing fears the Court would become a European patent graveyard.
#
​
Choosing your SEP battleground: UPC, Germany or UK?
07 June 2026
Choosing the right venue for SEP litigation can significantly influence the outcome of FRAND disputes. This article compares the UPC, German and UK courts, examining their approaches to injunctions, FRAND defences, rate-setting and enforcement. It highlights the strategic advantages of each jurisdiction and explains why many SEP owners are increasingly turning to the UK and UPC as part of their European enforcement strategy.
#
​
Synthetic Lethality & AI: IP Strategy in Oncology
26 May 2026
This article explores the resurgence of synthetic lethality in precision oncology, highlighting how AI and machine learning are accelerating the discovery of new therapeutic targets. It also examines growing clinical activity, investment, and the evolving intellectual property challenges shaping this emerging field.
#
​
Inside the Visser AI Launch Party
20 May 2026
EIP has officially launched Visser AI®, our hybrid intelligence service for patent drafting and prosecution. Watch the launch film from our event at The Boundary in Shoreditch, and discover how our team of European and US patent attorneys — working with the Patently AI platform , delivers faster, lower-cost work at the EPO, USPTO and beyond.
#
​
Protecting Your Startup: Five Intellectual Property Mistakes to Avoid
20 May 2026
Early‑stage startups often focus on product development and fundraising, but overlooking intellectual property (IP) can seriously damage long‑term value. This article explores five common IP mistakes startups make, with a particular focus on patents. It covers the risks of filing patents without professional advice, making public disclosures too early, failing to put enforceable contracts in place with third parties, misunderstanding what patent rights actually provide, and neglecting to develop a clear IP strategy. By highlighting these pitfalls and offering practical guidance, the article helps startups protect their innovations, strengthen their commercial position, and improve their prospects with investors.
#
​
Technology, Patents, and Sport
13 May 2026
VAR, goal-line tech, AI 3D player avatars, wearable trackers, the technology reshaping the 2026 World Cup and elite sport rests on a patent system that makes the R&D investment behind it worth taking.
#
​
Patents or Trade Secrets? When to Patent in Deep Tech Innovation
11 May 2026
Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.
#
​
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
​